Charles River Laboratories International, Inc.’s Stock Price Soars to $170.51, Marking a Robust 4.59% Increase

Charles River Laboratories International, Inc. (CRL)

170.51 USD +7.49 (+4.59%) Volume: 1.38M

Charles River Laboratories International, Inc.’s stock price is currently valued at 170.51 USD, witnessing a positive surge of +4.59% in the latest trading session with an active trading volume of 1.38M. Despite this recent uplift, the stock has experienced a percentage change of -7.53% YTD, showcasing the dynamic nature of CRL’s stock performance.

Latest developments on Charles River Laboratories International, Inc.

Recent events have led to significant movements in Charles River Laboratories‘ stock price today. The company has partnered with Conduit Pharmaceuticals to evaluate AZD1656 for lupus treatment, showcasing potential for future growth. Chairman James Foster’s purchase of 2.5% more shares reflects confidence in the company’s direction. Despite TD Cowen adjusting the price target slightly lower, executives at Charles River Laboratories have been making bold stock moves, with significant purchases and sales of shares recently. These transactions by top executives indicate a mix of confidence and strategic decision-making within the company, influencing stock price movements.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Charles River Laboratories International, Inc. has a mixed long-term outlook based on the Smartkarma Smart Scores. While the company scores well in terms of momentum, indicating strong performance in the market, its scores for value, growth, and resilience are more moderate. The company provides vital research tools and support services for drug discovery and development, serving a wide range of customers in the pharmaceutical and biotechnology industries, as well as hospitals and academic institutions.

Despite a lower score in the dividend category, Charles River Laboratories International, Inc. remains a key player in the research tools and support services sector. With a focus on providing animal research models for new drugs, devices, and therapies, the company plays a crucial role in the advancement of healthcare. Investors may want to consider the company’s overall performance across the various Smartkarma Smart Scores to make informed decisions about its long-term prospects.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma